A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Running, not enrolling · Phase 3

Conditions studied: Obesity, Overweight

In brief

The purpose of this study is to investigate the efficacy and safety of different retatrutide dose escalation schemes in participants without type 2 diabetes who have obesity or overweight. Participation in the study will last about 113 weeks.

Key facts

Study ID

NCT07357415

Run by

Eli Lilly and Company

People needed

600

Starts

2026-01-24

Expected to finish

2028-11-01

Last updated by the study team

2026-06-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a Body Mass Index (BMI) at screening
• ≥ 30 kilogram per square meter (kg/m2) OR
• ≥ 27 kg/m2 with presence of at least one of the following weight-related conditions at screening: high blood pressure, abnormal levels of lipid, obstructive sleep apnea, heart disease
• Have at least one unsuccessful attempt to lose weight by dieting

You may not qualify if…

• Have a self-reported change in body weight >5 kilograms (kg) (11 pounds) within 90 days before screening
• Have a prior or planned surgical treatment for obesity
• Have type 1 diabetes or type 2 diabetes
• Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
• Have had within the past 90 days before screening:
• heart attack
• stroke
• hospitalization for unstable angina or heart failure
• Have New York Heart Association Functional Classification Class IV congestive heart failure
• Have a history of chronic or acute pancreatitis
• Have taken weight loss drugs, including over-the counter medications within 90 days prior to screening

Where it is running

• Arizona Research Center — Phoenix, Arizona, United States
• Care Access - Huntington Beach — Huntington Beach, California, United States
• Los Angeles Institute for Metabolic Research — Los Angeles, California, United States
• New Horizon Research Center — Miami, Florida, United States
• Encore Medical Research - Weston — Weston, Florida, United States
• Pacific Diabetes & Endocrine Center — Honolulu, Hawaii, United States
• Monroe Biomedical Research - Louisville — Louisville, Kentucky, United States
• Brigham and Women's Hospital Diabetes Program — Boston, Massachusetts, United States
• Great Lakes Research Group, Inc. — Bay City, Michigan, United States
• NYC Research INC — Long Island City, New York, United States
• Weill Cornell Medical College — New York, New York, United States
• Care Access - Raleigh — Raleigh, North Carolina, United States
• New Phase Research and Development — Knoxville, Tennessee, United States
• Velocity Clinical Research, Dallas — Dallas, Texas, United States
• Cedar Health Research - Texas Native Health — Dallas, Texas, United States
• Cedar Health Research — Dallas, Texas, United States
• Cedar Health Research - Fort Worth — Fort Worth, Texas, United States
• Advanced Research Institute — Ogden, Utah, United States
• Dominion Medical Associates, Inc. — Richmond, Virginia, United States
• CAMC Institute for Academic Medicine — Charleston, West Virginia, United States
• Cicemo Srl — Buenos Aires, Argentina
• CARDIAMET Investigaciones Médicas — Buenos Aires, Argentina
• Stat Research S.A. — Buenos Aires, Argentina
• Centro de Investigaciones Metabólicas (CINME) — Buenos Aires, Argentina
• Centro Médico Viamonte — Buenos Aires, Argentina

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.